Skip to content
Bomb Report – Lifestyle
Author:
Ipsen Pharma
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
March 6, 2026
←
Previous Page
1
2